MaxCyte (NASDAQ:MXCT) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of MaxCyte (NASDAQ:MXCT) from a hold rating to a sell rating in a report published on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $7.00.

MaxCyte Stock Down 1.6%

Shares of MXCT stock opened at $0.77 on Friday. The company has a 50 day moving average of $1.03 and a 200-day moving average of $1.37. MaxCyte has a 12-month low of $0.64 and a 12-month high of $3.50. The firm has a market cap of $82.14 million, a P/E ratio of -1.75 and a beta of 1.22.

Institutional Investors Weigh In On MaxCyte

Hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its stake in shares of MaxCyte by 39.5% during the third quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company’s stock valued at $57,000 after purchasing an additional 10,263 shares during the period. Kwmg LLC increased its stake in shares of MaxCyte by 75.8% in the third quarter. Kwmg LLC now owns 25,833 shares of the company’s stock worth $41,000 after buying an additional 11,135 shares during the period. Prudential Financial Inc. bought a new stake in MaxCyte during the 2nd quarter valued at $26,000. State of Wyoming bought a new stake in MaxCyte during the 2nd quarter valued at $38,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in MaxCyte during the 2nd quarter valued at $40,000. Institutional investors own 68.81% of the company’s stock.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical?stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical?scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.